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Recently, it was shown that replication of bovine viral diarrhea virus (BVDV) is sensitive to inhibitors of host ER
glucosidases. Consistent with these findings, we report that incubation of BVDV-infected MDBK cells with the glucosidase
inhibitor n-butyl-deoxynojirimycin (nB-DNJ) reduced BVDV yields by 70- to 100-fold (n  27), while having no effect on MDBK
cell viability. However, the 70- to 100-fold reduction in infectious virus was associated with only a 2-fold reduction in genomic
RNA synthesis and secretion of enveloped virus particles. Analysis of secreted virions showed that in the absence of
glucosidase inhibitor, approximately 50% of the virion-associated BVDV E2 glycoprotein was resistant to endoglycosidase H
(endo H) digestion, whereas intracellular E2 was completely sensitive to endo H digestion. In the presence of glucosidase
inhibitor, virion-associated E2 and intracellular E2 were completely sensitive to endo H digestion. Taken together, these
results suggest that BVDV is secreted through a Golgi-mediated pathway and that host ER glucosidase activity is requiredINTRODUCTION
Many viruses require host ER glucosidase activity for
efficient replication and production of infectious particles
(Fisher et al., 1996a,b; Courageot et al., 2000; Lu et al.,
1997; Bolt et al., 1999; Zitzmann et al., 1999; Block et al.,
1998a). ER glucosidases I and II catalyze the sequential
removal of terminal glucose residues on nascent glyco-
proteins in the lumen of the ER (Cannon et al., 1996;
Cannon and Helenius, 1999). Trimming of the terminal
glucose residues yields monoglucosylated glycoproteins
which serve as substrates for calnexin and calreticulin,
host ER chaperone proteins that facilitate glycoprotein
folding (Cannon et al., 1996). Glucosidase inhibitors,
such as n-butyl-deoxynojirimycin (nB-DNJ), n-nonyl de-
oxynojirimycin (nN-DNJ), or castanospermine, inhibit glu-
cose trimming and block glycoprotein interaction with
calnexin and calreticulin, thereby greatly retarding the
rate of glycoprotein folding (Ellgaard et al., 1999; Cannon
et al., 1996). Glucosidase inhibitors do not dramatically
alter the function of many host proteins, since cell via-
bility is maintained at concentrations of compound that
inhibit viral glycoprotein function and prevent virion mor-
phogenesis or other critical steps in the virus life cycle
(Fisher et al., 1996a,b; Courageot et al., 2000; Lu et al.,
1997; Bolt et al., 1999; Zitzmann et al., 1999; Block et al.,© 2002 Elsevier Science (USA)
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101998a). Thus, glucosidases play an essential role in viral
glycoprotein folding and viral envelope function.
Bovine viral diarrhea virus (BVDV) is a pestivirus which
belongs to the Flaviviridae, a virus family that also com-
prises important human pathogens such as dengue vi-
rus, yellow fever virus, and hepatitis C virus. BVDV rep-
lication is sensitive to glucosidase inhibitors, suggesting
that viral glycoprotein processing is essential for virus
replication (Zitzmann et al., 1999). BVDV strain NADL
contains a total of 14 putative N-linked glycosylation
sites distributed among three glycoproteins termed Erns,
E1, and E2 (Donis, 1995). These glycoproteins along with
core protein comprise the major structural elements of
the virion and are likely required for receptor-mediated
entry into permissive cells (Donis et al., 1988; Donis and
Dubovi, 1987). Inhibition of N-linked glycosylation by ad-
dition of tunicamycin inhibits BVDV replication, suggest-
ing that cellular glycoprocessing is necessary for the
production of infectious virus (Donis and Dubovi, 1987).
The precise role of N-linked glycosylation in maturation
of BVDV is unknown.
In this report, initial studies were performed toward
understanding the role of ER glucosidases in the BVDV
life cycle. Using specific inhibitors of ER glucosidases,
the effects of these compounds on virus replication and
infectivity were examined. While glucosidase inhibitors
slightly reduced both BVDV genomic replication andfor production of infectious virions and Golgi processing of e
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virion secretion, the major impact upon virus replication
was the reduction of infectivity of newly synthesizednvelop
; glucos
m on
virions. Moreover, glucosidase inhibitors prevented
Golgi processing of virion-associated E2 glycoprotein.
These results suggest that BVDV virions are secreted
through a Golgi-mediated pathway and that ER glucosi-
dase activity is required for production of infectious viri-
ons and Golgi processing of E2 protein. Given the simi-
larities of BVDV replication with other members of the
Flaviviridae, ER glucosidases may serve as targets for
development of therapies for the treatment of flavivirus
infection.
RESULTS
The effects of -glucosidase inhibitors on BVDV
replication
Single-cycle BVDV replication. A previous report has
demonstrated that BVDV replication is sensitive to inhib-
itors of ER glucosidases in virus yield and plaque reduc-
tion assays (Zitzmann et al., 1999). In those experiments,
the effects of glucosidase inhibitors on BVDV replication
were studied at very low multiplicities of infection (0.001
PFU/cell), and virus yields were measured after multiple
rounds of infection. To measure the effects of glucosi-
dase inhibitors at low and high multiplicities of infection
in a single round of replication, MDBK cells were in-
fected with 0.05 or 5.0 PFU/cell of BVDV strain NADL in
the presence and in the absence of an amount of nB-DNJ
that was sufficient to inhibit 99% of the ER glucosidase
activity (4.5 mM). Virus yields were measured every 4 h
after infection for a 24-h period and the results are shown
in Fig. 1.
In this experiment, treatment of infected MDBK cells
with nB-DNJ reduced BVDV yields at 24 h postinfection
by 60-fold at a low (0.05 PFU/cell) multiplicity of infection
and 81-fold at a high (5.0 PFU/cell) multiplicity of infection
relative to untreated controls (Fig. 1). On average, treat-
ment of infected MDBK cells with 4.5 mM nB-DNJ re-
duced 24-h virus yields by 70-fold (n  27) relative to
untreated controls. Increasing the multiplicity of infection
from 0.05 to 5.0 PFU/cell had little effect on the antiviral
activity of nB-DNJ, suggesting that increasing the multi-
plicity of infection could not overcome the antiviral ef-
fects of the glucosidase inhibitor. Similar results were
obtained in 24-h yield assays with castanospermine, a
non-imino sugar glucosidase inhibitor, and n-nonyl-de-
oxynojirimycin, a derivative of nB-DNJ (data not shown).
The results of these tests demonstrated that BVDV rep-
lication is sensitive to inhibitors of host ER -glucosi-
dases in a single round of infection (Zitzmann et al.,
1999).
Previous studies have shown that glucosidase inhibi-
tors have a greater effect upon virus replication than
upon cell viability (Block et al., 1994b; Lu et al., 1997).
Indeed, the concentration of nB-DNJ needed to kill 50%
or the cells (CC50) was not reached and is therefore
greater than 38 mM, which was the highest concentra-
tion tested (data not shown). This concentration is well
above the concentration of inhibitor required to block
virus replication. Moreover, there was little observable
effect on cellular morphology at inhibitor concentrations
that reduced virus yield by 70-fold and inhibited glyco-
processing of secreted glycoproteins by 95% (data not
shown). Taken together, these results suggest that the
activity of viral glycoproteins with respect to production
of infectious virus is more sensitive to glucosidase inhi-
bition than the activity of many cellular proteins required
for host cell viability and protein secretion.
Viral RNA synthesis. To begin a determination of the
role of glucosidases in BVDV replication, the effects of
glucosidase inhibitors on BVDV genomic RNA synthesis
were examined. MDBK cells were either mock-infected
or infected with BVDV at 1 PFU/cell in the presence or
absence of nB-DNJ. At 20 h postinfection, newly replicat-
ing BVDV RNA was radiolabeled by the addition of [3H]-
uridine to the culture medium in the presence of actino-
mycin D (act D) (Purchio et al., 1983; Myers et al., 2001).
Act D was added to the cultures to reduce the back-
ground due to incorporation of radiolabel into cellular
mRNA. The BVDV RNA-dependent RNA polymerase is
resistant to act D at the concentrations used in these
FIG. 1. The effects of glucosidase inhibitors on single-cycle BVDV
replication. MDBK cells were infected in triplicate at a multiplicity of
infection of 0.05 PFU/cell (circles) or 5 PFU/cell (squares). At 1 h
postinfection the virus inoculum was removed and MDBK medium
alone (filled symbols) or containing 4.5 mM NB-DNJ (open symbols)
was added to the cultures. At 0, 4, 8, 12, 16, 20, and 24 hpi the cultures
were harvested and virus yields were measured by plaque assay. Error
bars represent the standard deviation from three infections.
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experiments and had no observable effect on BVDV
replication (Purchio et al., 1983). Total intracellular RNA
was isolated at 5 h postlabeling and separated by dena-
turing agarose gel electrophoresis (Fig. 2). The radiola-
beled RNA was visualized following autoradiography.
Radiolabeled BVDV genomic RNA from infected MDBK
cells migrated as a single species of approximately 12.5
kb, which is consistent with the reported size of 12.5 kb
for the full-length BVDV genome (Fig. 2, center and right
most lanes) (Collett et al., 1988). In mock-infected sam-
ples, no radiolabeled RNA was detectable at this molec-
ular weight (Fig. 2, left). The low-molecular-weight RNA
species (below the BVDV genomic RNA bands) comi-
grates with 28S and 18S rRNA. Virus yields were mea-
sured from duplicate cultures to determine the antiviral
efficacy of each compound (Fig. 2).
In the presence of nB-DNJ, the amount of radiolabel
incorporated into virus-specific RNA was 1.5-fold higher
in nB-DNJ-treated samples compared to untreated sam-
ples. In contrast, in the presence of nB-DNJ, the 24-h
yields of infectious BVDV were reduced by 2 logs relative
to untreated samples. Thus, while nB-DNJ had little effect
on uridine incorporation into BVDV RNA, there was a
more dramatic loss of infectious virus (100-fold). These
data indicate that glucosidase inhibitors block a step(s)
in the virus life cycle that occurs after RNA synthesis.
Virion secretion. It has been demonstrated that gluco-
sidase activity is required for assembly and secretion of
Dengue virus and Sinbis virus (McDowell et al., 1987;
Courageot et al., 2000). To determine whether glucosi-
dase inhibitors interfere with BVDV assembly and secre-
tion, the level of BVDV RNA in the medium was measured
by Northern blot analysis. MDBK cells were infected with
BVDV at 1 PFU/cell and treated with medium alone or
with medium containing 4.5 mM nB-DNJ. The medium
was collected at 24 h postinfection and virus yields were
measured by plaque assay and the level of BVDV RNA
was measured by Northern blot analysis (Fig. 3) (Sullivan
and Akkina, 1995). The Northern blots were probed with
radiolabel probes specific for the BVDV E2 gene.
Northern blot analysis detected a single RNA species
that migrated at the approximate molecular weight of
full-length BVDV RNA (12.5 kb) from BVDV-infected sam-
ples (Fig. 3, center and rightmost lanes). In mock-in-
fected samples, no RNA species were detected at this
molecular weight (Fig. 3, left lane). No appreciable dif-
ferences were observed in the level of secreted RNA in
the presence or in the absence of nB-DNJ (Fig. 3, center
and rightmost lanes). Similar results were obtained using
RT-PCR to measure the amounts of secreted BVDV RNA
(data not shown). In contrast, the 24-h virus yields were
reduced by 63-fold (Fig. 3, center and rightmost lanes).
These results suggest that glucosidase inhibitors had a
greater effect upon the production of infectious virus
than upon secretion of viral particles. Bovine actin mRNA
was not detected by RT-PCR in these RNA preparations,
while bovine actin mRNA was readily detectable in prep-
arations of MDBK cell RNA, suggesting that these virus
RNA preparations used for Northern blot and RT-PCR
analyses did not contain detectable cellular mRNA con-
tamination (data not shown). Taken together, these re-
sults suggest that glucosidase activity is required for the
production of infectious virus.
Virion infectivity. Equilibrium sedimentation was used
to test the role of glucosidases in the production of
infectious virus and to provide a more quantitative anal-
ysis of the effects of nB-DNJ on virus particle secretion.
MDBK cells were infected with 1 PFU/cell of BVDV in
the presence and absence of nB-DNJ and viral RNA was
FIG. 3. Northern blot analysis of secreted BVDV particles in the
presence and absence of nB-DNJ. Northern blot analysis of secreted
BVDV mRNA at 24 h postinfection from MDBK cells infected with BVDV
(NADL) at 1 PFU/cell and incubated in the presence and absence of
4.5 mM. Viral RNA from the supernatants was purified and transferred
to membranes by Northern blotting. The Northern blots were probed
with BVDV cDNA specific for E2. Virus yields in culture supernatants
were measured by plaque assay. The average reduction in virus yield
in the presence of 4.5 mM nB-DNJ is 65-fold.
FIG. 2. The effects of glucosidase inhibitors on BVDV RNA synthesis.
MDBK monolayers were infected with 5 PFU/cell BVDV and at 20 h
postinfection BVDV RNA was radiolabeled with [3H]uridine as de-
scribed under Materials and Methods. The radiolabeled RNA was
separated by denaturing agarose gel electrophoresis and visualized by
autoradiography. BVDV genomic RNA migrated as a single band of 12.5
kb. The two lower molecular weight species comigrate with 28S and
18S ribosomal RNA.
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radiolabeled by incorporation of radiolabeled uridine. At
24 h postinfection, secreted radiolabeled virions were
purified by PEG precipitation and sedimented to equilib-
rium on a 20 to 40% sucrose gradient. The amount of
radiolabeled material in each gradient fraction was de-
termined by TCA precipitation and liquid scintillation
counting. In addition, the amount of infectious virus in
every second fraction was measured by plaque assay
(Fig. 4).
Consistent with previously published reports, infec-
tious BVDV and radiolabeled RNA cosedimented at a
density of 1.10 g/cm3 (Parks et al., 1972). In control ex-
periments, removal of viral envelope by treatment of
virion preparations with 0.5% NP-40 prior to equilibrium
sedimentation eliminated the peak of infectivity and ra-
diolabeled material, suggesting that unenveloped virus
particles sediment at a different density than enveloped
virus under these conditions (data not shown). In the
presence of nB-DNJ, the migration of virus particles in
the gradient, as determined by the amount of radiola-
beled RNA in each gradient fraction, was shifted by one
fraction toward higher densities. This shift in particle
density was not consistently observed in replicative ex-
periments. These results suggest that there were no
gross alterations in virion structure in the presence of
glucosidase inhibitor that could be resolved by equilib-
rium sedimentation.
In the presence of nB-DNJ, the amount of infectious
virus in the peak fractions from the gradient was reduced
45-fold relative to the untreated controls. However, the
amount of radiolabeled RNA was reduced approximately
2-fold, suggesting that nB-DNJ had a greater effect on
virus infectivity rather than particle secretion. Since inhi-
bition of glucosidase activity did not dramatically affect
the incorporation of radiolabeled uridine into viral
genomic RNA (Fig. 2), the level of secreted radiolabeled
BVDV RNA was used as a surrogate marker for BVDV
particle number. Thus, comparing the level of BVDV RNA
to the level of infectious virus in peak fractions gave an
estimate of the relative infectivity of BVDV particles (par-
ticle to PFU ratio). The ratio of viral RNA to infectivity in
peak fractions from virus produced in the presence and
absence of nB-DNJ was 9.9  103 and 0.46  103
cpm/PFU, respectively. Thus, virus produced in the pres-
ence of nB-DNJ had a higher relative particle to PFU ratio
than virus produced in the absence of compound. The
results of these tests suggest that virions produced in
the presence of nB-DNJ are less infectious than virions
produced in the absence of glucosidase inhibitor.
FIG. 4. Equilibrium sedimentation of radiolabeled BVDV virions. MBDK monolayers were infected with 1 PFU/cell of BVDV. At 7 h postinfection
[3H]uridine was added to the cultures in the presence of actinomycin D and in the presence (squares) and absence (circles) of nB-DNJ. At 24 h
postinfection secreted virus was concentrated by PEG precipitation and sedimented to equilibrium on a 20 to 40% sucrose gradient. The amount of
radiolabeled material in each fraction was determined by TCA precipitation and liquid scintillation counting (open symbols and dashed lines). The
amount of infectious virus in every second fraction was measured by plaque assay (filled symbols and solid lines). The refractive index was used
to measure the density of each sample.
13THE ROLE OF GLYCOPROCESSING IN BVDV REPLICATION
Analysis of intracellular and virion-associated BVDV E2
glycoprotein. The reduced infectivity of virus particles
grown in the presence of glucosidase inhibitors sug-
gests that the loss of infectivity may be due to alterations
in virion glycoprotein function. BVDV E2 glycoprotein
contains a number of neutralizing epitopes, suggesting
that E2 participates in receptor-mediated virus entry. To
analyze the effects of glucosidase inhibitors on intracel-
lular and virion-associated E2, a monoclonal antibody
(WB166), specific for BVDV E2, was used to probe West-
ern blots of intracellular protein lysates prepared from
infected MDBK cell monolayers and from secreted and
PEG precipitated virion preparations (Figs. 5 and 6).
BVDV E2 migrated as a doublet of 53 and 60 kDa (Fig.
5, lane 2) on Western blots of intracellular protein lysates.
This doublet was due to incomplete proteolytic cleavage
at the C-terminus of E2 (Harada et al., 2000). Thus, two
forms of E2 are present in infected cells, E2 and unproc-
essed E2-p7, which differ in molecular weight by 7 kDa
(Harada et al., 2000).
In the presence of nB-DNJ the mobility of both E2 and
E2-p7 was retarded relative to untreated samples (Fig. 5,
lane 3). The reduced mobility of E2 in the presence of
nB-DNJ is likely caused by retention of terminal glucose
residues on N-linked oligosaccharides (Branza-Nichita
et al., 2001). Indeed, removal of all N-linked glycans by
endo F digestion caused both E2 and E2-p7 from un-
treated or nB-DNJ treated samples to migrate at approx-
imately 41 and 48 kDa, respectively (data not shown).
Thus, the increase in apparent molecular weight of E2
and E2-p7 in the presence of nB-DNJ was due to inhibi-
tion of glycoprocessing and not changes in proteolytic
processing.
To determine whether intracellular forms of E2 were
processed in the Golgi, protein lysates were treated with
endo H and analyzed by Western blotting. Endo H diges-
tion caused both E2 and E2-p7 to migrate at 41 and 48
kDa, respectively (Fig. 5, lanes 5 and 6), demonstrating
that both E2 and E2-p7 are sensitive to endo H digestion.
The apparent sensitivity to endo H digestion is consis-
tent with ER retention of Flaviviridae glycoproteins (Coc-
querel et al., 1998, 1999; Flint and McKeating, 1999).
Western blots of protein extracts from secreted and
PEG precipitated virus suspensions were used to mea-
sure the effects of glucosidase inhibitors on virion-asso-
ciated E2. Western blots of protein extracts from un-
treated samples showed that virion-associated E2 mi-
grated as a diffuse band of approximately 53 kDa (Fig. 6,
lane 2). In the presence of NB-DNJ, the virion-associated
E2 band was less diffuse and migrated at approximately
58 kDa (Fig. 6, lane 3). Removal of N-linked glycans by
endo F digestion caused virion-associated E2 protein
from both untreated and NB-DNJ-treated extracts to mi-
FIG. 6. The effects of nB-DNJ on posttranslational processing of
secreted virion-associated forms of BVDV E2. MDBK monolayers were
infected with BVDV at 1 PFU/cell in the presence and absence of 4.5
mM nB-DNJ. At 48 h postinfection the medium was collected and
secreted virions in the supernatant fluids were PEG precipitated. Pro-
tein lysates were prepared and incubated in the presence (lanes 4–6)
or absence (lanes 1–3) of endo H. The samples were analyzed by
Western blotting using WB166 monoclonal antibody specific for BVDV
E2 protein. The Western blots were developed as described in the
legend to Fig. 5. The Western blots were scanned to produce digital
images of each blot. (A) and (B) represent the results of two indepen-
dent experiments. The triangles denote the mobilities of glycosylated
(E2*) and deglycosylated E2.
FIG. 5. The effects of nB-DNJ on posttranslational processing of
intracellular forms of BVDV E2. MDBK monolayers were infected with
BVDV at 1 PFU/cell in the presence and absence of 4.5 mM nB-DNJ.
Protein lysates were prepared at 18 h postinfection and analyzed by
Western blotting. The Western blot was probed with monoclonal anti-
body WB166 specific for BVDV E2 protein and developed using alkaline
phophatase-conjugated goat anti-mouse antibodies and BCIP/NBT col-
orimetric substrates. The Western blot was scanned to produce a
digital image of the blot.
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grate with similar mobilities (data not shown). This result
suggests that the altered mobility of virion-associated E2
in the presence of glucosidase inhibitor is due to
changes in glycoprocessing.
To determine whether virion-associated E2 was pro-
cessed in the Golgi, protein lysates were treated with
endo H and analyzed by Western blotting. In the absence
of nB-DNJ, densitometric analysis of scans of the West-
ern blot indicated that approximately 50% of the virion-
associated E2 glycoprotein was resistant to endo H
digestion (Fig. 6, lane 5). Resistance to endo H digestion
is associated with Golgi-mediated processing. Partial
digestion by endo H was not due to loss of endo H
activity since RNase B, which was used as a control, was
digested to completion under the same reaction condi-
tions. Furthermore, incubation of endo H reaction mix-
tures for 24 h did not increase the amount of cleavage of
virion-associated BVDV E2 protein (data not shown).
These results suggest that BVDV is secreted through a
Golgi-mediated pathway and that a portion of the virion-
associated E2 glycoprotein is processed in the Golgi
during virus egress.
In the presence of nB-DNJ, treatment of virion extracts
with endo H showed that approximately 90% of the virion-
associated E2 glycoprotein was sensitive to endo H
digestion (Fig. 6, lane 6). This result suggests that glu-
cosidase inhibitors block Golgi processing of E2 or that
BVDV is secreted by a non-Golgi-mediated pathway.
DISCUSSION
In this article, we have shown that glucosidase inhib-
itors reduced the production of infectious virus in single-
round replication assays at low and high multiplicities of
infection. While these compounds reduced the produc-
tion of infectious virus, they had little effect on intracel-
lular BVDV RNA synthesis as measured by the incorpo-
ration of radiolabeled uridine into newly replicated ge-
nomes. Analysis of secreted BVDV RNA by Northern blot
analysis (Fig. 3) and RT-PCR (data not shown) showed
little effect on secretion of BVDV RNA in the presence of
glucosidase inhibitor. A more quantitative analysis of the
level of secreted virions as measured by equilibrium
sedimentation of radiolabeled virus particles demon-
strated that secretion of viral RNA was reduced 2-fold in
the presence of glucosidase inhibitor. While glucosidase
inhibitors reduced virion secretion by 2-fold, the reduc-
tion of infectious virus was much higher (70-fold), sug-
gesting that particles produced in the presence of glu-
cosidase inhibitors were less infectious. Indeed, analy-
sis of the infectivity of virus purified by equilibrium
sedimentation showed that virus from peak fractions
produced in the presence of glucosidase inhibitors was
45-fold less infectious relative to untreated samples.
Thus, while there are modest effects on virion secretion,
the predominant effect of glucosidase inhibitors on BVDV
replication was a reduction in the infectivity of newly
synthesized virus.
Zitzmann et al. (1999) have reported that glucosidase
inhibitors block BVDV replication. These studies were
performed in multiround replication assays at low multi-
plicity of infection and led them to conclude that gluco-
sidase inhibitors prevented the secretion of virus parti-
cles. This conclusion was based on the amount of se-
creted viral RNA measured by RT-PCR at 3 days
postinfection (Zitzmann et al., 1999). While our results are
consistent with a profound effect of glucosidase inhibi-
tors upon the virus life cycle, there are several important
differences. In contrast to Zitzmann and colleagues, we
have demonstrated that glucosidase inhibitors have little
effect on RNA synthesis and cause only slight (twofold)
reductions in virion secretion in single-round replication
assays. Moreover, we show that the predominant effect
of glucosidase inhibitors is on the infectivity of virus
particles. Zitzmann and colleagues concluded that glu-
cosidase inhibitors blocked the secretion of virus parti-
cles based on RT-PCR analysis of viral RNA following low
multiplicity of infection and multiple rounds of replication
over a period of 3 days. Since glucosidase inhibitors
reduced the infectivity of newly synthesized virus, multi-
ple rounds of replication would amplify the antiviral effect
and cause a larger difference in the amount of secreted
viral RNA between treated and untreated samples. In our
experiments, MDBK monolayers were infected at high
multiplicities of infection and samples were harvested
after a single round of replication. This method more
accurately reflects the magnitude of the antiviral effect in
a single round of infection and would show smaller
differences in the amount of secreted viral RNA in the
presence and in the absence of glucosidase inhibitor.
Secretion of BVDV is mediated through a Golgi-depen-
dent pathway since approximately 50% of the virion-
associated E2 glycoprotein on secreted virions is par-
tially resistant to endo H digestion. Resistance to endo H
digestion suggests that a portion of E2 was modified in
the Golgi during virus egress to produce oligosaccha-
rides containing high mannose and hybrid structures
which are resistant to endo H digestion. In the presence
of glucosidase inhibitor, virion-associated E2 was sensi-
tive to endo H digestion, suggesting that glucosidase
inhibitors prevented Golgi processing of virion-associ-
ated E2 or that virions were secreted by a non-Golgi-
mediated pathway. Intracellular forms of E2 were com-
pletely sensitive to endo H cleavage in the presence and
in the absence of glucosidase inhibitor, consistent with
ER retention of Flaviviridae glycoproteins (Cocquerel et
al., 1998, 1999; Flint and McKeating, 1999). Taken to-
gether, these results suggest that glucosidase inhibitors
reduced the infectivity of secreted virions and prevented
Golgi processing of BVDV E2 glycoprotein.
Inhibition of E2 Golgi processing or retention of termi-
nal glucose residues on viral glycoproteins caused by
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inhibition of glucosidase activity in the ER is not ex-
pected to contribute to the reduced infectivity of secreted
virions. BVDV replication is not inhibited by deoxyman-
nojirimycin (DMJ), a Golgi processing inhibitor which
blocks ER and Golgi mannosidases (Zitzmann et al.,
1999). Moreover, recent evidence examining the effects
of glucosidase inhibitors on HIV glycoprotein function
suggests that retention of terminal glucose residues on
viral glycoproteins caused by the inhibition of glucosi-
dase activity in the ER does not interfere with viral infec-
tivity. Glucosidase inhibitors caused a loss of reactivity of
monoclonal antibodies to surface epitopes on virion-
associated HIV gp120 which is involved in receptor-
mediated cell attachment. Removal of the terminal glu-
cose residues on gp120 did not restore monoclonal an-
tibody recognition to these epitopes (Fisher et al., 1996a).
These observations suggest that the effects of glucosi-
dase inhibitors on glycoprotein function occurred prior to
Golgi processing and virion secretion.
Inhibition of glucosidase activity affects viral
glycoprotein function
The current evidence is consistent with the theory that
inhibition of glucosidase activity reduces viral infectivity
by causing misfolding of viral glycoproteins. Glucosidase
inhibitors block glycoprotein interaction with host chap-
erone proteins and inhibit viral glycoprotein folding
(Parodi, 2000; Ou et al., 1993). Misfolded viral glycopro-
teins interfere with virion assembly, virion secretion,
and/or infectivity of newly synthesized virus (Fisher et al.,
1996a,b; Courageot et al., 2000; Schlesinger et al., 1985,
2000). Thus, interaction with ER chaperones is an impor-
tant component of viral glycoprotein biogenesis. Copre-
cipitation experiments have shown that both BVDV and
HCV glycoproteins E1 and E2 interact with calnexin
(Choukhi et al., 1998; Branza-Nichita et al., 2001). In
addition, VSV G protein and influenza hemagglutinin di-
rectly bind to calnexin (Cannon et al., 1996; Hebert et al.,
1997). Thus, the exquisite sensitivity of viral glycopro-
teins to glucosidase inhibitors may reflect the inability of
viral glycoproteins to achieve their native conformations
in the absence of interaction with ER chaperones.
Indeed, it has been demonstrated that glucosidase
inhibitors cause aberrant intracellular BVDV E1–E2 het-
erodimer formation, suggesting that these proteins are
incorrectly folded (Branza-Nichita et al., 2001). The re-
duced infectivity of BVDV virions produced in the pres-
ence of glucosidase inhibitors may reflect incorporation
of one or more misfolded glycoproteins that are required
for binding or postbinding events during infection.
Several virus systems provide evidence in support of
this hypothesis. Glucosidase inhibitors reduced infectiv-
ity of measles virus without causing major alterations in
virion protein composition or viral protein processing
(Bolt et al., 1999). Measles virus produced in the pres-
ence of glucosidase inhibitors exhibited reduced reac-
tivity to neutralizing monoclonal antibodies, suggesting
that there are alterations in conformation-dependent
epitopes on the virus surface required for infectivity (Bolt
et al., 1999). Likewise, glucosidase inhibitors caused
changes in reactivity of HIV virions to neutralizing mono-
clonal antibodies and blocked HIV replication and HIV-
induced syncytia formation by inhibiting postbinding
events (Fisher et al., 1996a,b). While the processing of
HIV gp160 is altered in the presence of glucosidase
inhibitors and some unprocessed gp160 is incorporated
into the virion, the major effect of these compounds is
alteration of the V1/V2 region of gp120, which is involved
in HIV binding to cell receptors (Fisher et al., 1996a,b).
Taken together, these results suggest that glucosidase
inhibitors induce conformational changes in surface
epitopes of viral glycoproteins required for infectivity.
Potential therapeutic target for HCV and other
flavivirus infections
BVDV and HCV are flaviviruses that have similar
genomic structures and likely share similar replication
strategies. Thus, BVDV is often used as a model for HCV
infection (Zitzmann et al., 1999; Ryan et al., 1998). While
glucosidase inhibitors reduced the infectivity of secreted
BVDV virions, the effects of these compounds on HCV
replication is unknown. Unlike BVDV, cell lines that sup-
port high-level replication of HCV are currently unavail-
able; therefore, infectivity of HCV virions produced in the
presence of glucosidase inhibitors cannot be assessed.
In vitro systems have been established to study the
biogenesis and function of HCV glycoproteins (Choukhi
et al., 1998; Pileri et al., 1998). In these systems, gluco-
sidase inhibitors produced a 20% reduction in the
amount of native HCV E2–E1 heterodimers (Choukhi et
al., 1998). Formation of native E2–E1 dimers is thought to
be required for virion function (Choukhi et al., 1998).
However, glucosidase inhibitors had no observable ef-
fect on HCV E1–E2 interaction to the putative cellular
receptor, CD81 (Chan-Fook et al., 2000). While glucosi-
dase inhibitors have no noticeable effect on glycoprotein
biogenesis or function, it is possible that glucosidase
inhibitors would block postbinding events in a manner
similar to what has been observed for HIV infection
(Fisher et al., 1996a,b). Moreover, HCV envelope glyco-
proteins, like BVDV, may be postranslationally modified
by Golgi enzymes during virus egress and thus viral
glycoprotein activity would not be fully realized until virus
particles are secreted. Without a reliable infectivity
model for HCV replication, the effects of glucosidase
inhibitors on HCV infection remain unknown. Thus, glu-
cosidase inhibitors may serve as novel antiviral thera-
pies for the treatment of HCV and other flavivirus infec-
tions.
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MATERIALS AND METHODS
Cells, viruses, and glucosidase inhibitors
Madin–Darby bovine kidney cells (MDBK, ATCC-
CCL22) were grown in DMEM/F12 (Gibco BRL, Gaithers-
burg, MD) supplemented with 10% heat-inactivated horse
serum (Gibco BRL). MDBK cells were tested for BVDV
contamination by RT-PCR as described (Sullivan and
Akkina, 1995). The cytopathic (cp) NADL strain of BVDV
was kindly provided by Dr. Ruben Donis, University of
Nebraska, and was prepared by transfection of infec-
tious RNA transcribed in vitro from an infectious cDNA
clone (Vassilev et al., 1997). The resulting virus stock was
plaque-purified three times on MDBK cell monolayers
prior to large-scale virus stock preparation.
The glucosidase inhibitor nB-DNJ was provided by
Synergy Pharmaceuticals (Sommerset, NJ).
BVDV single-cycle replication
MDBK cells (3  105 cells per 20-mm-diameter well)
were infected in triplicate at a multiplicity of infection
(m.o.i.) of 0.05 or 5 PFU/cell. At 1 h postinfection, the virus
inoculum was removed, and the monolayers were
washed twice with 1 ml of MDBK medium. MDBK me-
dium, in the presence and in the absence of 4.5 mM
nB-DNJ, was added to the cultures. At 0, 4, 8, 12, 16, 20,
and 24 h postinfection the cultures were harvested and
frozen at 70°C. The cultures were thawed at 37°C and
immediately sonicated (Heat Systems ultrasonicator,
Farmington, NY) at 40% power for 30 s at 0°C to release
cell-associated virus. Cell debris was removed by cen-
trifugation at 1000 g for 10 min at 4°C and virus yields in
the supernatant fluids were measured by plaque assay.
Plaque assay for measuring virus yields
MDBK monolayers (3  105 cells per 20-mm-diameter
well) were infected with 100 l of 10-fold dilutions of virus
suspensions. At 1 h postinfection the inoculum was re-
moved and the monolayers were washed once with
MDBK medium, and 1 ml of MDBK medium containing
1% methyl cellulose overlay was added to the monolay-
ers. Since most plaques were counted at the 104 dilu-
tion of virus suspension, the concentrations of glucosi-
dase inhibitors that might be present in the virus sus-
pension were well below the concentrations needed to
inhibit virus replication.
BVDV genomic RNA synthesis
BVDV genomic RNA synthesis was measured by the
method of Purchio et al. (1983). MDBK monolayers (7 
105 cells per 35-mm-diameter dish) were infected with
1 PFU/cell of BVDV. At 1 h postinfection the monolayers
were washed twice with 1 ml of MDBK medium. MDBK
medium alone or medium containing 4.5 mM nB-DNJ
was added to the cultures. At 20 h postinfection, medium
containing actinomycin D (5 g/ml) in the presence and
in the absence of glucosidase inhibitor was added to the
cultures. Following a 2-h incubation in the presence of
actinomycin D, 50 Ci/ml [5,6-3H]uridine (43 Ci/mmol)
was added to the culture medium and the cultures were
incubated for 5 h. Total intracellular RNA was isolated
using the Ultraspec RNA isolation system according to
the manufacturer’s specifications (Biotecx Laboratories,
Inc., Houston, TX). The RNA was denatured by treatment
with 1 M glyoxal in 50% DMSO for 1 h at 50°C and
separated by electrophoresis on a 0.7% agarose gel. The
gel was treated with 3% 2,5-diphenyloxazole in meth-
anol–water and dried under vacuum. The radiolabeled
BVDV RNA was visualized by autoradiography. The au-
toradiographic images following 12, 24, and 48 h of
exposure were used to determine the pixel density in
each band by densitometry.
Northern blot analysis
MDBK cell monolayers (7  105 cells per 35-mm-
diameter dish) were infected with BVDV at 1 PFU/cell.
At 1 h postinfection the cultures were washed twice with
1 ml MDBK medium and the cultures were incubated
with medium alone or 4.5 mM nB-DNJ medium. At 24 h
postinfection cell culture supernatants were prepared by
centrifugation of medium at 1000 g for 10 min at 4°C to
remove cell debris. Virus yields were determined from a
portion of the supernatant fluids. The remaining super-
natant fluids were incubated with 0.25% SDS and 200
g/ml proteinase K for 20 min at 50°C. The samples
were extracted twice with an equal volume of buffer-
saturated phenol:chloroform:isoamyl alcohol (25:24:1,
v/v) and once with an equal volume of chloroform:
isoamyl alcohol (24:1, v/v). The RNA was precipitated in
ethanol and collected by centrifugation at 14,000 g for 15
min at 4°C. The RNA was denatured in 1 M glyoxal for
1 h at 50°C and separated on a 0.7% agarose gel in
sodium phosphate buffer (Ausubel et al., 2001). The RNA
was transferred to nylon membrane by Northern blotting
and probed with 32P-radiolabeled cDNA specific for the
BVDV E2 gene. The Northern blot was visualized by
phosphorimager analysis.
Equilibrium centrifugation
Equilibrium sedimentation of BVDV virions was per-
formed as described by Pritchett et al. (1975) with the
following modifications. MBDK monolayers (1.5  107
cells per 225-cm2 flask) were infected with BVDV at 1
PFU/cell. At 6 h postinfection, 0.1 g/ml actinomycin D in
the presence and in the absence of 4.5 mM nB-DNJ was
added to the cultures. At 7 h postinfection total RNA was
labeled by addition of 100 Ci/ml [5,6-3H]uridine (43
Ci/mmol) to the culture medium. At 24 h postinfection the
cultures were harvested and cell debris was removed by
centrifugation at 1000 g for 10 min at 4°C. Virus in the
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supernatant fluids was precipitated in 10% polyethylene
glycol (PEG, 8000 MW) and collected by centrifugation at
10,000 g for 60 min at 4°C. The PEG precipitate was
resuspended in 1 ml of TEN buffer (10 mM Tris–HCl, pH
7.6, 150 mM NaCl, 1 mM EDTA) and layered onto a 14-ml
10 to 40% continuous sucrose gradient prepared in TEN
buffer. The samples were centrifuged to equilibrium at
90,000 g for 24 h at 4°C. The amount of radiolabeled
material in each fraction from the gradient (0.4 ml) was
measured by TCA precipitation and liquid scintillation
counting. The amount of infectious BVDV in every second
fraction was measured by plaque assay.
Western blotting
MDBK monolayers (1.5  107 cells per 225-cm2 flask)
were infected with BVDV at 1 PFU/cell in the presence
and in the absence of 4.5 mM nB-DNJ. At 18 h postin-
fection the infected cell monolayers were scraped into
1 PBS and the cells were collected by centrifugation at
1000 g for 10 min at 4°C. The cell pellet was resus-
pended in 500 l of lysis buffer (10 mM Tris–HCl, pH 7.6;
150 mM NaCl; 1 mM EDTA; 0.5% IGEPAL CA-630; 1
protease inhibitor cocktail; Sigma Inc., St. Louis, MO;
Catalog No. P8340) and incubated for 5 min on ice. The
insoluble debris was removed by centrifugation at 1000 g
for 5 min at 4°C. An equal volume of 2 SDS–PAGE
sample buffer was added to supernatant fluids which
were stored at 80°C. Secreted virions were collected
at 48 h postinfection and precipitated by the addition of
PEG (8000 MW) to 10% in TEN buffer. The PEG precipi-
tates were collected by centrifugation at 20,000 g for 60
min at 4°C and resuspended in 500 l TEN buffer.
Virus samples from PEG precipitated material and
intracellular protein lysates were analyzed by SDS–PAGE
and Western blotting. Protein concentrations were deter-
mined by Bradford assay and equal amounts of protein
were loaded in each lane of the gel. The Western blots
were probed with a monoclonal antibody WB166 specific
for BVDV E2 protein (Central Veterinary Laboratories,
Surrey, UK). The Western blots were developed using
alkaline phophatase-conjugated goat anti-mouse anti-
bodies (Sigma Inc.) and BCIP/NBT colorimetric sub-
strates. Densitometric analysis of scans of the Western
blots was performed to quantify the relative amounts of
each protein species.
Treatment of protein extracts with endo H (Boehinger
Mannheim, Indianapolis, IN) was performed according to
the manufacturer’s recommendations. RNase B and Fe-
tuin (Sigma Inc.) were used as positive and negative
controls, respectively. RNase B was completely digested
by endo H during the 1-h incubation period while Fetuin
was resistant to endo H cleavage.
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